ABO-1009DP is under clinical development by Suzhou Abogen Biosciences and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ABO-1009DP’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ABO-1009DP overview

ABO1009-DP is under development for the prevention of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant. It is a mRNA vaccine and is administered through intramuscular route.

Suzhou Abogen Biosciences overview

Abogen Biosciences, is a developer of China’s first messenger ribonucleic acid vaccine against Covid-19 to begin clinical trials. The company is headquartered China.

For a complete picture of ABO-1009DP’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.